~ Nov 07 How Much Abuse Should Cancer Patients Have to Take?

By William Faloon

In this eye-opening report, we reveal how and why effective FDA-approved treatments are often ignored by the cancer establishment and what cancer patients can now do about it.

Over the past twelve months, Life Extension has been interacting with a group of oncology researchers and clinicians to develop a program that would enable cancer patients to gain access to the most advanced science-based treatments.

While preparing to launch this aggressive new program, the New York Times published an article that further emphasized the need to radically change the way cancer treatment is delivered.1

Most lay people are not familiar with non-Hodgkin's lymphoma, but it is the fifth most common cancer in the United States and causes 20,000 annual deaths.2 Jacqueline Kennedy Onassis died from non-Hodgkin's lymphoma in May of 1994.

The New York Times reported on FDA-approved drugs that have been shown to be more effective in treating non-Hodgkin's lymphoma than existing chemotherapies.1 The problem is that oncologists don't make as much money prescribing these better drugs because they have to be administered in the hospital setting.

How much better are the newer drugs? In a 2002 study published in the Journal of Clinical Oncology, 80% of patients who received one of the new drugs (Zevalin®) with chemotherapy showed tumor shrinkage, compared with only 56% of those who received the older drug (Rituxan®) with chemotherapy.

In patients who received Zevalin®, 30% went into complete remission compared with only 16% who got Rituxan®.3

The New York Times conducted interviews with the few fortunate lymphoma patients whose oncologists prescribed these newer drugs. These human beings are convinced they would be dead if they had to rely on the older drugs, which had already failed them.

Conventional chemo drugs are big money-makers for oncologists who administer them intravenously in their offices. Instead of referring non-Hodgkin's lymphoma patients to a hospital setting for the better drugs, some oncologists commit the barbarous act of administering the older, less effective drugs in order to earn more money for them.

Examples of patients being exposed to toxic and less than optimal treatments run rampant in clinical cancer practice. While radiation therapy has a place in treating certain cancers, it has become so profitable that it is being inappropriately used in many settings, as are other conventional treatments that Medicare fully and unquestionably reimburses.

For 27 years, Life Extension has been battling an entrenched cancer establishment that places its profits over cancer patients who entrust their very lives to this corrupt system. With the establishment of the new International Strategic Cancer Alliance (ISCA), enlightened cancer patients can now gain access to the very best treatments, without any financial bias to distort what should only be a scientific decisionmaking process.

A New Solution for Cancer Patients: The International Strategic Cancer Alliance

"Empowering Patients with Knowledge and Comprehensive Care"

A cancer diagnosis is often the most frightening event in a person's life. An equally distressing aspect is the challenge of locating an oncology group with expertise in providing the most up-to-date and creative treatments for your particular type of cancer.

Those diagnosed with cancer today find themselves at a historical crossroad. Despite multiple options to choose from, no medical facility integrates cancer treatment into a comprehensive program based on the totality of the scientific data available.

The result is that it is a challenge to provide patients with the optimal opportunity to achieve long-term survival.

Cancer is a complex disease that requires a multimodality therapy to provide the best chances of attaining a cure. Discoveries occur quickly in the research setting, but the process by which they are incorporated into clinical oncology practice is excruciatingly slow.

In order to fully avail oneself of a science-based treatment protocol, the cooperation of a motivated and knowledgeable oncology group is mandatory.

Until recently, the burden of acquiring enough information to take advantage of science-based synergistic treatment programs has fallen on the cancer victim or the caregiver.

A new organization called the International Strategic Cancer Alliance (ISCA) has been formed to unite patients with oncologists who will integrate a vast array of synergistic therapies into customized treatment programs to provide the best scientific opportunity of eradicating the malignancy.

The ISCA is currently focused on assistance to newly diagnosed prostate and breast cancer patients.

The Alliance also facilitates the design and implementation of human clinical trials for cancer patients. A medical advisory board has been formed to assist with the program's goals. The client base of ISCA already includes international participants.

Why Cancer Treatment Must Be Individualized

Curing malignant disease is not simple. Cancer cells are everything we would like healthy cells to be: They quickly adapt to toxic environments, they readily alter themselves to assure their continued survival, and they utilize biologic mechanisms to promote cellular immortality. All of these factors make cancer an extremely difficult disease to treat.

Chemotherapy drugs have a high rate of failure because they usually kill only specific types of cancer cells within a tumor. The remaining cancer cells are then free to mutate and become highly resistant to were incorporated into clinical medicine.

What has long concerned the founders of the International Strategic Cancer Alliance is that respected cancer journals publish articles that identify safer and more effective treatment regimens, yet few oncologists incorporate these improved methods into their clinical practice.

Cancer patients often suffer through surgery, radiation, and chemotherapy treatments that do not integrate the latest synergistic or additive scientific findings.

One purpose of the ISCA is to direct patients to oncology groups that incorporate multimodal approaches in order to improve the probability of a successful outcome.

The ISCA also considers the use of an integrative approach for the purpose of lowering the side effects of patients' cancer treatments.

It is impossible to design a single chemotherapy protocol that is effective against all types of cancer. The oncologist might need to administer several chemotherapy drugs at varying doses and different times because tumor cells express survival factors with a wide degree of individual cell variability.

The ISCA brings together oncologists who utilize findings from published scientific studies to provide additional treatments that have a logical basis to augment the effects of chemotherapy, reduce the potential for side effects, and block the many survival mechanisms that cancer cells use to escape destruction with conventional therapies.

For the first time, cancer patients can gain access to a team of dedicated professionals who will delve deep into the molecular aspects behind each individual's disease and then use the fruits of published scientific literature in a practical manner for the benefit of the cancer patient.
International Strategic Cancer Alliance: What You Need to Know
  • Today's mainstream cancer care system is deeply flawed, compensating oncologists based on the number of patients they treat each day and giving bonuses for prescribing certain drugs. As a result, patients often receive less-than-optimal care and are not advised of the most advanced cancer-fighting therapies available.

  • Innovative oncology researchers and clinicians have established the International Strategic Cancer Alliance (ISCA) to provide patients with the most advanced cancer care available today.

  • By customizing treatment, incorporating multimodal therapies, utilizing the latest research findings, and helping patients access experimental therapies, the ISCA seeks to find the cure for each individual's cancer.

  • The ISCA utilizes a team of experts to offer advanced care, while a patient advocate helps coordinate care and answer all of the patient's questions and concerns.

  • If you or your loved one is fighting cancer, contact the ISCA to determine if this cutting-edge approach can be of assistance.

Why Mainstream Oncologists Can't Keep Up

Virtually everyone remembers a time when medical doctors were revered with unwavering trust. This physician respect was well deserved, since those who contracted illness often had nowhere else to turn.

In conventional medicine's bygone golden era, doctors routinely delivered state-of-the-art care. One reason yesteryear's physicians kept abreast of new developments was that medical progress back then was very slow.

In other words, it was notparticularly difficult to prescribe the best standard treatment, since medical advancements occurred at such an agonizingly sluggish pace.

Oh, how times have changed! For any given disease, there are more new scientific studies published in a month than previously came out in a year.

In the field of cancer research, the pace of research findings is exploding even faster.

The problem is that it has become impossible for practicing oncologists, who often see 30 or more patients a day, to stay current with what has become an avalanche of new discoveries related to better ways of treating cancer.

In today's world, scientific information is plentiful, which creates an unsettling predicament for those suffering from cancer.

The dilemma is that a significant amount of time and expertise is required to review complex medical literature and then translate the data into a practical treatment plan.

A dedicated information gatherer can spend hundreds of hours poring over thousands of scientific reports that pertain to any type and stage of cancer.

While the reliability of these reports varies, the undeniable fact is that the proper utilization of these data could mean the difference between life and death to those with severe disease.

The difficulty is that even with advanced electronic communications and data mining, practicing oncologists lack the time needed to analyze every new study published in the world's medical journals.

The quandary faced by patients is that their very lives may be at stake, yet up until now, they have had nowhere to turn to uncover novel therapies that could result in a cure, or at least a significant alleviation of their disease.

The premise behind the programs advocated by the International Strategic Cancer Alliance is to direct patients to oncology groups who are translating this vast amount of new discoveries into practical treatment protocols for the immediate benefit of the individual patient.

Those who believe in controlling their own destiny will appreciate how this translational research approach can augment the weapons already available to combat their disease.

Why Don't Major Cancer Centers Cure More Cancer Patients?

Major cancer centers often operate in a manner analogous to a bureaucratic assembly line. Oncologists are paid high salaries to see 30 or more cancer victims a day.

The typical schedule of an oncologist can involve seeing patients from 7:00 a.m. to 10:00 p.m. five days a week and then being on call during several weekends each month. On certain nights, the overworked oncologist has to be woken by emergency calls.

Even strongly motivated oncologists lack the time to come close to providing optimal comprehensive care to each patient. At some major medical centers, oncologists are paid "chemotherapy bonuses," which can make up a substantial percentage of their compensation.

This financial incentive helps explain why some terminal cancer patients are poisoned with chemotherapy drugs when there is no hope it will cure their disease.Regrettably, there is no financial incentive for practicing oncologists to actually "cure" their patients.

Big dollars are made by squeezing as many cancer patients as possible into a hectic day in order for the oncologist to earn a higher salary and receive larger chemotherapy bonuses. It does not require much imagination to see why today's cancer "industry" has such a high patient failure rate.

There simply is no mechanism in place to provide cancer patients with the customized therapies that are required if optimal care is to be provided. Today's overworked oncologists are forced into a work environment that rates success based on how many patients they can bill for in a given day, week, or month.

Oncologists who desire to augment their conventional protocols with novel strategies can actually lose money, since the profitable "assembly line" might have to be altered to accommodate the time it takes to evaluate and then administer additional therapies.
Analyzing Each Individual's Tumor Cells

The ISCA has worldwide contacts for some of the best analytical laboratories for:
  1. High-quality pathology tests of tumor biopsy samples

  2. Chemosensitivity testing

  3. Testing of circulating tumor cells for advanced-stage cancer.
ISCA has a contract with a European laboratory, which performs DNA analysis of circulating tumor cells. Numerous molecular markers are available for the detection of circulating tumor cells in the bloodstream. If circulating tumor cells are detected, then a chemosensitivity test is performed, which provides a list of both chemo drugs and nutraceutical agents that can be applied against those cells. A sample report for a breast cancer patient is shown below:

















Analysis

Result

Unit

Glutamat-Cystein-Synthetase (GCS) mRNA

0.92

 

Glutation-S-Transferase PI (GST-PI) mRNA

0.27

 

Mn-abhangige Superoxiddismutase mRNA

0.58

 

Telomerase mRNA

4.93

 

ERBB2 mRNA

2.49

 

C-MYC mRNA

1.30

 

GAPDH mRNA

462000

oeq

GAPDH mRNA Tumorzellfraktion

4765

oeq

Multidrug-Resistenz-Gen 1 (MDR-1) mRNA

0.00

 

Multidrug-Resistenz ass. Protein 1 mRNA

0.95

 

Thymidilat-Synthetase (TS) mRNA

0.98

 

Desoxycytidin-Kinase (DCK) mRNA

1.52

 


Dehydrofolat-Reduktase (DHFR) mRNA

6.35

 

MGMT mRNA

2.70

 

Topoisomerase II (TOPO II) mRNA

1.72

 

ERCC1 mRNA

1.20

 

BFGF mRNA



8.20

 

VEGF mRNA

0.38

 

Ostrogen-Rezeptor mRNA

1.11

 

Aromatase mRNA

1.49

 

C-Kit mRNA

3.90

 

PDGF-Rezeptor-beta (p65) mRNA

0.38

 

Farnesyl-Transferase mRNA

1.11

 

NF-kappa-B (p65) mRNA

1.49

 

Heat-shock Protein 27 (HSP27) mRNA

3.90

 


A Team Approach Dedicated to Achieving Positive Results

If the International Strategic Cancer Alliance is to succeed, it must demonstrate positive results. It has no established clinical practice to rely on. The ISCA instead must depend solely on referrals from nonprofit patient support groups and satisfied patients.

The ISCA represents a team of dedicated individuals whose mission to show the world that cancer today is woefully undertreated and that utilizing creative customized treatment protocols is far superior to "assembly line" oncology practice.

If a cancer patient is initially deemed curable, then ISCA will make heroic efforts to effect a cure.

If the patient is considered terminal, ISCA will either reject the patient outright, or accept the patient if there is a possibility of providing a significant extension of the life-span prognosis.

There will be no false hope given, just a war-time mentality that every conceivable therapy that has been documented in a published scientific study should be made available based on individual patient need. What Does this Cost?

Fees for the personalized services provided by International Strategic Cancer Alliance are billed on an hourly basis. Hourly rates range from $125 to $450 depending on the time utilized by nurse practitioners, consultants and the treating oncologist.

If one has good medical insurance, the costs of the standard cancer treatments administered by the treating oncologist may be covered.

In some cases, ISCA will recommend the creative use of approved drugs that are not insurance-reimbursable.

In these cases, the drugs may have to be paid for directly by the patient.

The patient will also probably be responsible for other creative treatments recommended by the treating oncologist working with ISCA. The patient will be advised about all costs before treatments are administered so they can decide whether to pay for a particular treatment.

To initiate a relationship with ISCA, a required $10,000 retainer is put into an escrow account and then billed out each month based on the hours spent working on the individual patient's case. In some cases, a refund of unused escrow fees will be made, while more difficult cases will require additional retainer deposits.

The ISCA hopes that patients understand that significantly more time will be expended on their case than would be provided by a conventional oncologist.

The ISCA believes the additional time spent designing and monitoring customized treatment protocols will provide better long-term outcomes for patients.

Reality, however, dictates that someone must pay for the many professional hours spent seeking to provide each patient with optimal comprehensive treatment.

A Service that Money Cannot Buy Elsewhere

At least one out of every three Americans will be stricken with cancer. 10 Included in these grim statistics are the rich and famous. Unlike any other service, well-to-do individuals often wind up with the same mediocre cancer treatment as an average person with health insurance.

Oncology is practiced today in a somewhat socialized fashion, where standard treatments are provided to virtually everyone. In today's world, a billionaire could offer an oncology group limitless money in exchange for a cure, but this would do little good, since most conventional doctors are incapable of "thinking outside the box."

As a client of the International Strategic Cancer Alliance, you gain access to an entirely new sciencebased approach to cancer treatment.

If appropriate, you will receive some of the same conventional therapies as would be prescribed by mainstream oncologists. The ISCA then goes beyond these standard treatments by seeking to incorporate every novel synergistic or additive strategy that may provide a greater opportunity to achieve a complete response or cure.

The mission of the ISCA is to change the way oncology is practiced. To accomplish this radical goal, ISCA must be able to show hard statistical data that the comprehensive multimodal therapies it utilizes are achieving superior results compared with mainstream medicine.

In order for ISCA to transform the world of oncology, the clients it services have to obtain better results than what is delivered today. There is no place in the world where you could buy this focused and dedicated objective towards saving your life.

No matter how much money you had to offer, this unique service is simply not available anywhere else.

Evidence for assumed drug responses results from the analyses of chemoresistance markers and drug target genes in the tumor cell fraction. According to the panel of genetic markers we have analyzed, the following conclusions are drawn:

THERAPIES WITHOUT INDICATIONS OF RESISTANCE:

Taxanes (paclitaxel/docetaxel): due to the undetectable expression of the resistance factor MDR, resistance to taxanes mediated by MDR is not anticipated.

Alkylating agents-nitrogen mustards (e.g. cyclophosphamide, ifosphamide): sensitivity to these drugs is assumed because GST and GCS were not found overexpressed.

Vinca-alkaloids (e.g. vinblastine, vinorelbine): according to the measured expression levels of the resistance factors GCS, MDR and MRP, resistance to these drugs is not assumed.

Mitomycin: deduced from the measured expression levels of MDR, GST, and GCS, resistance to mitomycin is not expected.Lapatinib/Herceptin: as a consequence of the elevated expression of ERBB2, a response of the tumor cells to these agents is indicated.

DRUGS WITH RESTRICTED SENSITIVITY:

Anthracyclines: (e.g. doxorubicin, epirubicin) and mitoxantrone; although the expression levels of the resistance factors MDR, MRP, GST and GCS do not indicate resistance to these drugs, the observed basis-level expression of the drug-target topoisomerase II suggests no increased sensitivity of the tumor cells compared to normal cells.

Gemcitabine: due to the observed base-level expression of DCK in the tumor cells resistance to Gemcitabine is not expected, but an increased sensitivity compared to normal cells is also not assumed.

DRUGS WITH MINOR THERAPEUTICAL EFFICACY EXPECTED:

Tyrosine-Kinase-Inhibitors (Sorafenib/Sunitinib/Gleevec): these drugs act as inhibitors of tyrosine-kinase like C-KIT or PDGF-R-beta. In the isolated tumor cells, expression of the PDGF-R-beta and C-KIT was downregulated. Therefore, the tumor cells may not respond in a suitable way to treatment with these compounds.

Platinum compounds (cis/carboplatin): resistance of the tumor cells to platinum compound treatment is expected due to the observed over-expression of HSP27.Methotrexate and Pemetrexed: the observed overexpression of DHFR suggests resistance to these compounds.

Alkylating agents-nitrosoureas (e.g. carmustine, lomustine): the cells showed overexpression of MGMT. Resistance to these compounds is therefore expected.

Tamoxifen: since the estrogen-receptor was not expressed, a response to treatment with tamoxifen mediated by this receptor is unlikely.

Aromatase-inhibitors (e.g. Anastrozole, Femara): expression of aromatase and estrogen-receptor was not detected. Therefore, these drugs may not act in a proper way on the tumor cells.

VEGF-inhibitors (e.g. Avastin): due to the observed downregulation of VEGF-expression, minor sensitivity of the circulating tumor cells to VEGF-inhibitors is assumed.

Bortezomib (Velcade): the observed elevated expression of HSP27 suggests only minor response to bortezomib.

Hyperthermia: HSP27 was overexpressed in the isolated tumor cells. This may lead to thermoresistance of the tumor cells and a reduced efficiency of hyperthermia therapy.

Suggested Supportive AlteRnative Therapies:

The observed elevated expression of HSP27 may reduce the efficacy of hyperthermia. To overcome HSP27-related resistance, administration of the anti-HSP27 agent Quercetin may be considered.

FAVORABLE ALTERNATIVE THERAPIES:
  • Overexpression of telomerase was observed in the tumor cells. Treatment with the alternative agent inositol-6-phosphate (IP6), described as an inhibitor of telomerase may therefore be considered.

  • The angiogenesis promoting factor bFGF was overexpressed in the tumor cells. A therapy with C-statin, an inhibitor of bFGF may therefore be considered.
Note: Any alternative treatment should only be done under the supervision of an experienced health professional.

Free Consultation

To become a client of International Strategic Cancer Alliance, please call 610-628-3419 for a free consultation. Patients will not be accepted if their cancer is too far advanced, or if they are unwilling to travel to locations that may provide superior care.

For patients who are candidates for ISCA's customized programs, it is important that they feel comfortable in working with their personal advocate, ergo the free consultation available to cancer patients and/or their family members.

References . . .


Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.